Skip to main content
Premium Trial:

Request an Annual Quote

Full-Life Technologies Closes $47.3M Series B Financing

NEW YORK – Full-Life Technologies on Thursday said it raised $47.3 million in Series B equity financing, which it will use to advance a pipeline of radiopharmaceuticals for cancer, build out manufacturing capabilities, and optimize its discovery platform.

Prosperity7 Ventures and an undisclosed healthcare specialist investor led the round, which also included Sky9 Capital, Summer Capital, GuanghuaWutong Fund, and existing investors Chengwei Capital, HongShan, and Junson Capital.

In conjunction with the financing, Full-Life has secured a $16 million loan facility, which provides the firm flexible financing for developing its therapeutic pipeline and constructing a radiopharmaceutical manufacturing plant in Belgium.

Shanghai-based Full-Life expects to begin Phase I clinical studies of its lead candidate 225Ac-FL-020 in metastatic castration-resistant prostate cancer in Europe and the US in early 2024. The drug comprises a PSMA-targeting vector, FL-020, designed to deliver actinium-225. The company said that in preclinical studies, 225Ac-FL-020 has shown promising anti-tumor activity.

Full-Life in May raised $37 million in a Series A financing round and has brought in more than $110 million in funds from equity financing, loans, and government subsidies since it was founded in August 2021.